Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Myelodysplastic Syndrome
NCT00977548Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2009
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Moffitt Cancer Center. Started Sep 2009; status: completed.
02
Drugs
erlotinib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00977548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00977548.